Bristol-Myers Squibb Company or Insmed Incorporated: Who Invests More in Innovation?

Bristol-Myers vs. Insmed: A Decade of R&D Investment

__timestampBristol-Myers Squibb CompanyInsmed Incorporated
Wednesday, January 1, 2014453400000056292000
Thursday, January 1, 2015592000000074277000
Friday, January 1, 20164940000000122721000
Sunday, January 1, 20176411000000109749000
Monday, January 1, 20186345000000145283000
Tuesday, January 1, 20196148000000131711000
Wednesday, January 1, 202011143000000181157000
Friday, January 1, 202110195000000272744000
Saturday, January 1, 20229509000000397518000
Sunday, January 1, 20239299000000571011000
Monday, January 1, 202411159000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Bristol-Myers Squibb Company and Insmed Incorporated are two players with distinct strategies. Over the past decade, Bristol-Myers Squibb has consistently outpaced Insmed in research and development (R&D) spending. In 2023, Bristol-Myers Squibb invested approximately 16 times more in R&D than Insmed, highlighting their commitment to innovation.

From 2014 to 2023, Bristol-Myers Squibb's R&D expenses grew by over 100%, peaking in 2020 with a 150% increase from 2014. Meanwhile, Insmed's R&D spending, though smaller, showed a steady upward trend, increasing by nearly 900% over the same period. This growth reflects Insmed's strategic focus on niche markets and specialized treatments.

As the pharmaceutical landscape evolves, these investment patterns reveal the companies' differing approaches to innovation and market leadership.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025